Skip to content
AnalystLens

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2025

Filing Date
Filed February 20, 2026
Period End
December 31, 2025
Security
IDXX
One revenue dollarkept$0.25
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Nov ’20Nov ’20
  2. Material agreement8-K · Oct ’22Oct ’22
  3. Leadership change8-K · Feb ’25Feb ’25

Summary

Summary of the 10-K filed February 20, 2026. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories (IDXX) closed 2025 with record results: revenue rose 10.4% reported (9.6% organic) to $4.30 billiona, and income from operations grew 20.5% to $1.36 billion, with operating margin expanding about 260 basis points to 31.6%.

Net income reached $1.06 billionb and diluted EPS was $13.08, up from $10.67 in 2024. Growth was led by the Companion Animal Group (CAG), where recurring diagnostic revenue (about 79% of consolidated revenue) rose 8.9%, driven by IDEXX VetLab consumables (+14.8%) and reference laboratory services (+6.6%). The new IDEXX inVue Dx cytology analyzer drove a 51.8% increase in instrument revenue.

Gross margin improved to 61.8%c and the installed base of premium instruments grew about 12%. The filing also flags headwinds that investors should weigh. Management expects U.S. same-store clinical visits to decline roughly 2% again in 2026, reflecting veterinary capacity constraints and macroeconomic pressure, and it projects a higher 2026 effective tax rate of about 21.3%.

Operating cash flow was strong at $1.18 billiond, but free cash flow after $125 million of capex was reduced by a roughly $80 million litigation payment. Capital returns were heavy: about $1.2 billion was spent repurchasing about 2.4 million shares, and the company guided to a further 1% to 2% reduction in diluted shares in 2026. Leverage remains modest, with a gross debt to Adjusted EBITDA ratio of 0.54x against a 3.5x covenant.

Management also announced a planned CEO transition in May 2026. Risk factors emphasize concentration in a few key suppliers, including Ortho for Catalyst chemistry slides, along with rising competition from Mars-owned and Zoetis businesses, consolidation of corporate veterinary hospitals, and evolving AI, PFAS, and data-privacy regulation. Management reports that its internal controls over financial reporting were effective and that PwC issued an unqualified audit opinion.

Key Highlights

  1. Revenue grew 10.4% to $4.30 billion (9.6% organic), with CAG contributing $3.95 billion, up 10.6%.
  2. Income from operations rose 20.5% to $1.36 billion, and gross margin expanded 80 basis points to 61.8%.
  3. Diluted EPS increased to $13.08 from $10.67, while net income reached $1.06 billion.
  4. Recurring diagnostic revenue was about 79% of consolidated revenue, supported by IVLS consumables growth of 14.8% and a 12% increase in the premium instrument installed base.
  5. The IDEXX inVue Dx analyzer launch lifted CAG instrument revenue 51.8% to $200 million.
  6. Management guides to a roughly 2% decline in U.S. same-store clinical visits in 2026 and a 21.3% effective tax rate.
  7. The company returned about $1.2 billion through buybacks in 2025 and plans a further 1% to 2% reduction in diluted shares in 2026; leverage is low at 0.54x gross debt to Adjusted EBITDA.

Follow one dollar

Of each $1.00 of revenue in FY2025, IDEXX Laboratories kept $0.25.

  1. Revenue$4.30B100.0%
  2. Cost of revenue−$1.64B38.2%
  3. Gross profit$2.66B61.8%
  4. Operating costs−$1.30B30.2%
  5. Operating income$1.36B31.6%
  6. Interest, other & tax−$300.6M7.0%
  7. Net income$1.06B24.6%
Computed from 10-KFY2025filed February 20, 2026Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2025 revenue went

$4.30B
  • Cost of revenue: $1.64B, 38% of revenue
  • Net income: $1.06B, 25% of revenue
  • Other operating costs: $1.05B, 24% of revenue
  • R&D: $251.2M, 5.8% of revenue
  • Interest, other & tax: $300.6M, 7.0% of revenue

Kept 25% as net income

Full revenue history →

Financial Statements

FY2025 against FY2024

Line itemFY2025FY2024Change
Revenue$4.30B$3.90B+10.4%
Cost of Revenue$1.64B$1.52B+8.3%
Gross Profit$2.66B$2.38B+11.8%
R&D Expenses$251.21M$219.79M+14.3%
Operating Expenses$1.30B$1.25B+3.9%
Operating Income$1.36B$1.13B+20.5%
Net Income$1.06B$887.87M+19.3%
EPS (Basic)$13.17$10.77+22.3%
EPS (Diluted)$13.08$10.67+22.6%
Shares Outstanding (Basic)80.43M82.47M−2.5%
Shares Outstanding (Diluted)81.03M83.25M−2.7%

Frequently Asked Questions

  1. How strong was IDEXX's 2025 revenue and profit growth?

    Revenue grew 10.4% reported and 9.6% organically to $4.30 billion. Income from operations rose 20.5% to $1.36 billion, and diluted EPS increased 23% to $13.08, aided by operating leverage and a 260 basis point gain in operating margin.

  2. What is driving recurring revenue at IDEXX?

    Recurring CAG diagnostic revenue grew 8.9% to $3.41 billion. IDEXX VetLab consumables rose 14.8% on higher volumes and prices, reference laboratory services rose 6.6%, and the premium instrument installed base grew about 12%, all of which support future consumables sales.

  3. What risks does the filing highlight for 2026?

    Management expects U.S. same-store clinical visits to decline about 2% again, a higher effective tax rate near 21.3%, and ongoing tariff and inflation pressure. Other flagged risks include supplier concentration (notably Ortho for Catalyst slides), competition from larger rivals, corporate consolidation of veterinary hospitals, and a planned CEO transition in May 2026.

  4. How is IDEXX deploying its cash?

    In 2025 the company generated $1.18 billion of operating cash flow, spent $125 million on capex, and repurchased about $1.2 billion of stock. It has no dividend and expects to fund a $75 million senior note maturity in September 2026 from cash or its credit facility, leaving leverage conservative at 0.54x gross debt to Adjusted EBITDA.

  5. Are there any one-time items affecting 2025 comparisons?

    Yes. The prior year included a $61.5 million litigation expense, and in 2025 IDEXX paid about $80 million to settle a royalty lawsuit that had been accrued in earlier years. The payment reduced operating cash flow but did not affect 2025 operating income because it was previously expensed.